department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Zyclara · pharmadog

pharmadog
drugs
Zyclara

drug

patient view →

Zyclara

Marketedupdated 2mo ago

by Bausch Health US LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Zyclara

generic

imiquimod

indication

Genital Warts (Condylomata Acuminata)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 18, 2029

~3.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Apr 30, 2030method-of-use (U-1455)US 109186353.8y
Apr 30, 2030method-of-use (U-172)US 112027523.8y
Apr 30, 2030method-of-use (U-172)US 118502453.8y
Dec 11, 2029method-of-use (U-68)US 102386443.4y
Dec 11, 2029method-of-use (U-68)US 113181303.4y
Dec 11, 2029method-of-use (U-68)US 82222703.4y
Dec 11, 2029method-of-use (U-68)US 82368163.4y
Dec 11, 2029method-of-use (U-68)US 82991093.4y
Aug 18, 2029method-of-use (U-1455)US 102386453.1y
Aug 18, 2029method-of-use (U-1455)US 85981963.1y

Data sources

ClinicalTrials.gov

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying Zyclara

phase2Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinomarecruitingn=18
phase1A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomasactive not recruitingn=15
phase1A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumorsactive not recruitingn=138
phase3Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesionscompletedn=91
phase4Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%completedn=485
phase4Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimodrecruitingn=96
phase2Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiformecompletedn=74
phase3Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesionscompletedn=4,446

more trials →